Print this page

Targeted Cancer Therapy

Nordic Nanovector AS is a privately held company based in Oslo, Norway. The company was established in 2009. Our mission is to develop innovative radioimmunotherapeutics that target difficult to treat cancers using the company’s proprietary nanovector targeting technology.

Nordic Nanovector intends to commercialise its product candidates through strategic alliances and partnerships with experienced oncology businesses and by establishing its own sales and marketing capabilities in selected markets.





September 1, 2014

Nordic Nanovector: – Subsequent Offering
Press Relase 24/2014. See link for details.

August 29, 2014
Nordic Nanovector: – Approved prospectus
Press Relase 23/2014. See link for details.
Click links below to see Prospectus:
http://www.abgsc.com/Content/Transaction-documents/Nordic-Nanovector-AS---Subsequent-Offering/

https://www.dnb.no/bedrift/markets/emisjoner/arkiv/140828-nordic-nanovector.html#

August 26, 2014
Nordic Nanovector: Second Quarter Report 2014
Press Relase 22/2014. See link for details.
See: Second Quarter Report 2014










Next page: About us